Free Trial

Edgewise Therapeutics (EWTX) Competitors

Edgewise Therapeutics logo
$14.59 -0.28 (-1.88%)
Closing price 04:00 PM Eastern
Extended Trading
$14.58 -0.02 (-0.10%)
As of 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EWTX vs. LEGN, TLX, VRNA, LNTH, AXSM, TGTX, GRFS, NUVL, ADMA, and PCVX

Should you be buying Edgewise Therapeutics stock or one of its competitors? The main competitors of Edgewise Therapeutics include Legend Biotech (LEGN), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Verona Pharma (VRNA), Lantheus (LNTH), Axsome Therapeutics (AXSM), TG Therapeutics (TGTX), Grifols (GRFS), Nuvalent (NUVL), ADMA Biologics (ADMA), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.

Edgewise Therapeutics vs.

Legend Biotech (NASDAQ:LEGN) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

In the previous week, Legend Biotech had 23 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 37 mentions for Legend Biotech and 14 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.28 beat Legend Biotech's score of 0.79 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Legend Biotech
14 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive
Edgewise Therapeutics
13 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Legend Biotech has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500.

Legend Biotech presently has a consensus target price of $74.73, indicating a potential upside of 163.77%. Edgewise Therapeutics has a consensus target price of $40.22, indicating a potential upside of 175.68%. Given Edgewise Therapeutics' higher possible upside, analysts clearly believe Edgewise Therapeutics is more favorable than Legend Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Legend Biotech
0 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.92
Edgewise Therapeutics
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.78

Edgewise Therapeutics has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Legend Biotech$728.30M7.14-$518.25M-$0.59-48.02
Edgewise TherapeuticsN/AN/A-$100.16M-$1.55-9.41

Legend Biotech received 52 more outperform votes than Edgewise Therapeutics when rated by MarketBeat users. Likewise, 73.02% of users gave Legend Biotech an outperform vote while only 72.73% of users gave Edgewise Therapeutics an outperform vote.

CompanyUnderperformOutperform
Legend BiotechOutperform Votes
92
73.02%
Underperform Votes
34
26.98%
Edgewise TherapeuticsOutperform Votes
40
72.73%
Underperform Votes
15
27.27%

70.9% of Legend Biotech shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 23.2% of Edgewise Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Edgewise Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -66.92%. Edgewise Therapeutics' return on equity of -26.83% beat Legend Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Legend Biotech-66.92% -29.69% -19.45%
Edgewise Therapeutics N/A -26.83%-25.67%

Summary

Legend Biotech beats Edgewise Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Edgewise Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EWTX vs. The Competition

MetricEdgewise TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.53B$6.48B$5.35B$8.38B
Dividend YieldN/A2.66%5.22%4.10%
P/E Ratio-9.738.9226.8419.71
Price / SalesN/A250.96391.39116.98
Price / CashN/A65.8538.2534.62
Price / Book3.226.466.794.50
Net Income-$100.16M$143.98M$3.23B$248.18M
7 Day Performance0.27%3.04%4.07%1.14%
1 Month Performance9.70%7.44%12.52%15.20%
1 Year Performance-18.45%-2.46%16.83%6.56%

Edgewise Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EWTX
Edgewise Therapeutics
2.9231 of 5 stars
$14.59
-1.9%
$40.22
+175.7%
-20.8%$1.53BN/A-9.7360Positive News
LEGN
Legend Biotech
3.5386 of 5 stars
$32.38
+1.9%
$78.82
+143.4%
-33.8%$5.95B$627.24M-34.081,070News Coverage
Analyst Revision
TLX
Telix Pharmaceuticals Limited American Depositary Shares
N/A$16.25
-5.4%
$22.00
+35.4%
N/A$5.49B$783.21M0.00N/AGap Down
VRNA
Verona Pharma
2.6775 of 5 stars
$67.53
+6.6%
$81.50
+20.7%
+484.7%$5.48B$118.54M-35.1730Positive News
LNTH
Lantheus
4.458 of 5 stars
$79.52
-2.7%
$132.67
+66.8%
-7.3%$5.45B$1.54B13.23700Positive News
High Trading Volume
AXSM
Axsome Therapeutics
4.7267 of 5 stars
$110.16
+2.2%
$172.14
+56.3%
+39.7%$5.42B$432.16M-18.39380Positive News
Insider Trade
TGTX
TG Therapeutics
3.8254 of 5 stars
$34.99
+4.0%
$40.80
+16.6%
+115.2%$5.34B$386.39M-349.87290Positive News
GRFS
Grifols
3.2195 of 5 stars
$7.73
+8.9%
N/A+4.7%$5.31B$7.21B6.6126,300Positive News
NUVL
Nuvalent
2.6421 of 5 stars
$73.63
+5.4%
$115.50
+56.9%
+7.0%$5.27BN/A-21.2240News Coverage
Positive News
ADMA
ADMA Biologics
3.1796 of 5 stars
$20.45
+2.4%
$24.25
+18.6%
+117.2%$4.86B$459.38M73.04530News Coverage
Positive News
Gap Down
PCVX
Vaxcyte
3.0977 of 5 stars
$31.59
+1.4%
$136.50
+332.1%
-51.8%$4.08BN/A-6.87160News Coverage
Positive News
Earnings Report
Gap Up

Related Companies and Tools


This page (NASDAQ:EWTX) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners